Cargando…

Histopathological efficacy of tacrolimus in an experimental head trauma study

BACKGROUND: This study aimed to investigate the protective effect of tacrolimus (FK506), an immunosuppressive agent, on secondary brain damage in rats with experimental head trauma. METHODS: 40 Sprague-Dawley rats, aged 10–12 weeks and weighing 250–350 g, were used without gender selection. The subj...

Descripción completa

Detalles Bibliográficos
Autores principales: Atadağ, Ali, Erkutlu, İbrahim, Bozkurt, Ahmet Sarper, Eronat, Ömer, Atadağ, Yıldız Büyükdereli, Üçler, Necati, Geyik, Abidin Murat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kare Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198338/
https://www.ncbi.nlm.nih.gov/pubmed/36748776
http://dx.doi.org/10.14744/tjtes.2023.33644
_version_ 1785044727322640384
author Atadağ, Ali
Erkutlu, İbrahim
Bozkurt, Ahmet Sarper
Eronat, Ömer
Atadağ, Yıldız Büyükdereli
Üçler, Necati
Geyik, Abidin Murat
author_facet Atadağ, Ali
Erkutlu, İbrahim
Bozkurt, Ahmet Sarper
Eronat, Ömer
Atadağ, Yıldız Büyükdereli
Üçler, Necati
Geyik, Abidin Murat
author_sort Atadağ, Ali
collection PubMed
description BACKGROUND: This study aimed to investigate the protective effect of tacrolimus (FK506), an immunosuppressive agent, on secondary brain damage in rats with experimental head trauma. METHODS: 40 Sprague-Dawley rats, aged 10–12 weeks and weighing 250–350 g, were used without gender selection. The subjects that were divided into five groups of 8 rats per group (sham control, negative control, positive control, vehicle control, and treatment) were sacrificed 1 month after head trauma was induced under appropriate conditions, their brains were then removed en bloc and evaluated histopathologically. Secondary brain injury was evaluated with the immunoreactive score (IRS) after Glial Fibrillary Acid Protein staining of gliosis that would occur in brain tissue. RESULTS: The evaluation of the histopathological IRS values of all groups showed significant statistical differences between all groups. The pairwise group comparison revealed the highest increase in IRS value in the treatment group (p<0.05), with no statistical significance despite the increase in the negative control, positive control, and vehicle control groups. The sham group had the lowest rate of severe histopathological reaction score. CONCLUSION: It was observed that the group treated with FK506 had a statistically significant increase in gliosis in the traumatic area compared to the other control groups. This shows that FK506 cannot prevent and even increase gliosis by a mechanism that has not yet been clarified. In conclusion, it is obvious that the FK506 immunosuppressive agent does not reduce post-traumatic brain injury; on the contrary, it increases gliosis.
format Online
Article
Text
id pubmed-10198338
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Kare Publishing
record_format MEDLINE/PubMed
spelling pubmed-101983382023-06-02 Histopathological efficacy of tacrolimus in an experimental head trauma study Atadağ, Ali Erkutlu, İbrahim Bozkurt, Ahmet Sarper Eronat, Ömer Atadağ, Yıldız Büyükdereli Üçler, Necati Geyik, Abidin Murat Ulus Travma Acil Cerrahi Derg Experimental Study BACKGROUND: This study aimed to investigate the protective effect of tacrolimus (FK506), an immunosuppressive agent, on secondary brain damage in rats with experimental head trauma. METHODS: 40 Sprague-Dawley rats, aged 10–12 weeks and weighing 250–350 g, were used without gender selection. The subjects that were divided into five groups of 8 rats per group (sham control, negative control, positive control, vehicle control, and treatment) were sacrificed 1 month after head trauma was induced under appropriate conditions, their brains were then removed en bloc and evaluated histopathologically. Secondary brain injury was evaluated with the immunoreactive score (IRS) after Glial Fibrillary Acid Protein staining of gliosis that would occur in brain tissue. RESULTS: The evaluation of the histopathological IRS values of all groups showed significant statistical differences between all groups. The pairwise group comparison revealed the highest increase in IRS value in the treatment group (p<0.05), with no statistical significance despite the increase in the negative control, positive control, and vehicle control groups. The sham group had the lowest rate of severe histopathological reaction score. CONCLUSION: It was observed that the group treated with FK506 had a statistically significant increase in gliosis in the traumatic area compared to the other control groups. This shows that FK506 cannot prevent and even increase gliosis by a mechanism that has not yet been clarified. In conclusion, it is obvious that the FK506 immunosuppressive agent does not reduce post-traumatic brain injury; on the contrary, it increases gliosis. Kare Publishing 2023-02-01 /pmc/articles/PMC10198338/ /pubmed/36748776 http://dx.doi.org/10.14744/tjtes.2023.33644 Text en Copyright © 2022 Turkish Journal of Trauma and Emergency Surgery https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Experimental Study
Atadağ, Ali
Erkutlu, İbrahim
Bozkurt, Ahmet Sarper
Eronat, Ömer
Atadağ, Yıldız Büyükdereli
Üçler, Necati
Geyik, Abidin Murat
Histopathological efficacy of tacrolimus in an experimental head trauma study
title Histopathological efficacy of tacrolimus in an experimental head trauma study
title_full Histopathological efficacy of tacrolimus in an experimental head trauma study
title_fullStr Histopathological efficacy of tacrolimus in an experimental head trauma study
title_full_unstemmed Histopathological efficacy of tacrolimus in an experimental head trauma study
title_short Histopathological efficacy of tacrolimus in an experimental head trauma study
title_sort histopathological efficacy of tacrolimus in an experimental head trauma study
topic Experimental Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198338/
https://www.ncbi.nlm.nih.gov/pubmed/36748776
http://dx.doi.org/10.14744/tjtes.2023.33644
work_keys_str_mv AT atadagali histopathologicalefficacyoftacrolimusinanexperimentalheadtraumastudy
AT erkutluibrahim histopathologicalefficacyoftacrolimusinanexperimentalheadtraumastudy
AT bozkurtahmetsarper histopathologicalefficacyoftacrolimusinanexperimentalheadtraumastudy
AT eronatomer histopathologicalefficacyoftacrolimusinanexperimentalheadtraumastudy
AT atadagyıldızbuyukdereli histopathologicalefficacyoftacrolimusinanexperimentalheadtraumastudy
AT uclernecati histopathologicalefficacyoftacrolimusinanexperimentalheadtraumastudy
AT geyikabidinmurat histopathologicalefficacyoftacrolimusinanexperimentalheadtraumastudy